Document is current

Article History

Received: 9 May 2020

Accepted: 13 July 2020

First Online: 22 July 2020

Compliance with ethical standards

:

: AK reports grants and personal fees from Taiho, grants and personal fees from Ono, grants from Sumitomo Dainippon, and grants from MSD, outside the submitted work. DT reports grants and personal fees from Taiho Pharmaceutical Co. and Ono Pharmaceutical Co., and personal fees from Eli Lilly Japan, Bristol-Myers Squibb, Yakult Honsha Co., Ltd., and Chugai Pharmaceutical Co., Ltd., outside the submitted work. CK has nothing to disclose. YN reports research funding from Taiho Pharmaceutical. TI has nothing to disclose. MW reports personal fees from Chugai Pharmaceutical Co., Ltd. and personal fees from Johnson & Johnson K.K. MEDICAL COMPANY, outside the submitted work. SN reports personal fees from AstraZeneca, personal fees from Taiho Pharmaceutical, personal fees from Chugai, and personal fees from Pfizer, outside the submitted work. HT has nothing to disclose. MF has nothing to disclose. NH has nothing to disclose. YS has nothing to disclose. MK has nothing to disclose. AS has nothing to disclose. KS reports receiving payment for consulting or advisory roles from Astellas, Lilly, Bristol-Myers Squibb, Takeda, Pfizer, Ono, and MSD; honoraria from Novartis, AbbVie, and Yakult; and research funding from Astellas, Lilly, Ono, Sumoitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, MSD, and Medi Science.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

: Informed consent or substitute was obtained from all patients for being included in the study.

Free to read: This content has been made available to all.